Michael Andreeff
Chief, Section of · University of Texas M D Anderson Cancer Center
Credentials: · · ·
History
- Present
Section of · University of Texas M D Anderson Cancer Center
- 1976–1977
1st Medical Clinic
- 1973–1976
Internal Medicine
- 1970–1975
Medical Policlinic
University
Research
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
New England Journal of Medicine · 1991 · 1,289 citations
Cancer Cell · 2006 · Last of 26 authors · 892 citations
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas
Cancer Research · 2005 · 852 citations
260 papers
189 papers
112 papers · 1 as a fellow
- GB
95 papers
95 papers · 1 as a fellow
93 papers
79 papers
73 papers
Grants
- 2019–2027
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Food and Drug Administration · R01
Contact PI · $1.2M · University of Tx Md Anderson Can Ctr
- 1996–2026
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $11M · University of Tx Md Anderson Can Ctr
- 2022–2024
National Cancer Institute · R21
Contact PI · $412K · University of Tx Md Anderson Can Ctr
- 2008–2018
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
National Cancer Institute · P50
Project lead · $1.4M · University of Tx Md Anderson Can Ctr
Clinical trials
- 2010–2017
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
- 1998–2008
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
- 1992–2002